Evoke Pharma Reaffirms Its Commitment To Improving The Lives Of Patients Suffering From Diabetic Gastroparesis In Light Of The Recent Decision By The U.S. FDA To Not Approve Vanda Pharmaceuticals NDA For Tradipitant, An Oral Drug Candidate For The Treatment Of Symptoms In Gastroparesis
Portfolio Pulse from Benzinga Newsdesk
Evoke Pharma reaffirms its commitment to treating diabetic gastroparesis following the FDA's decision not to approve Vanda Pharmaceuticals' drug candidate, Tradipitant. Evoke's Gimoti® remains the only FDA-approved nasal spray for this condition.
September 19, 2024 | 6:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Evoke Pharma's commitment to diabetic gastroparesis treatment is highlighted as the FDA rejects Vanda's Tradipitant. Evoke's Gimoti® remains the only FDA-approved nasal spray for this condition.
The FDA's rejection of a competing product, Tradipitant, potentially strengthens Evoke Pharma's market position with its Gimoti® nasal spray, the only FDA-approved treatment for diabetic gastroparesis. This could positively impact Evoke's stock in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
Vanda Pharmaceuticals faces a setback as the FDA does not approve its drug candidate, Tradipitant, for gastroparesis treatment.
The FDA's decision not to approve Tradipitant is a negative development for Vanda Pharmaceuticals, likely leading to a short-term negative impact on its stock price.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 70